BeyondSpring triples on positive results for lung cancer drug

Beyondspring

04/08/2021 14:26

** Shares of pharmaceutical company  BYSI.O  surge more than
three-fold premarket to an over three-year high of $32.5, on
course to jump by the most on record 
    ** Co announces positive data from Phase 3 trial of its lead
drug, plinabulin, in combination with docetaxel to treat
non-small cell lung cancer  urn:newsml:reuters.com:*:nGNXd9WVs
    ** Study met primary goal of the trial showing statistically
significant improvement in overall survival for the combination
of plinabulin and docataxel
    ** BYSI plans to seek approval from U.S. and Chinese health
regulators for plinabulin in combination with docetaxel based on
the demonstrated clinical benefit and safety profile
    ** The phase 3 trial is a randomized global trial that
enrolled 559 patients with measurable lung lesion
    ** Upt o Tuesday's close, stock has lost 21% this year

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))